dc.description.abstract | Based on current available evidences, the mutations in tyrosine kinase domain of epidermal growth factor receptor (EGFR) was significantly associated with clinical responsiveness to tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC). Retrospective studies showed that EGFR tyrosine kinase mutation in tumor specimen was as an independent predictive factor of clinical outcomes for TKI treated patients. Patients with mutations would have better clinical response to TKI and longer overall survival in comparison with wild-type patients. The mutation rate was 30 to 42% in Asian patients, higher than Caucasian patients. However, the relationship between clinical responsiveness to chemotherapy and its impact on survival and EGFR mutations was unclear in patients with advanced NSCLC. In this study, we investigated the influence of EGFR mutations in tumor specimens on the clinical outcomes of advanced NSCLC patients who received chemotherapy as 1st or 2nd line treatment.
In total, 86 patients with available tumor specimens were selected from these clinical trials of NSCLC, which conducted at the Department of Oncology, National Taiwan University Hospital. Tumor sequencing in exon 18 through 21 of EGFR, and retrospective collection of clinical data of patients were performed. RESULTS: 34.9% of patients had EGFR mutations. 44.2% of patients had a partial response to chemotherapy. The mutations in subgroups – more frequently found in patients with adenocarcinoma than patients with other histologic types (40.3% vs 13.3%, p=.05), in female than male (39.4% vs 32.1%, p=.49). The mutation rates were 34.9%, 25.9%, 50.0%, respectively in patients who had never smoked, currently smoked, and formerly smoked. The L858R substitution mutation in exon 21 was the most common mutation in 53.3% of all mutations. The in-frame deletions located around E746-A750 in exon 19 were second frequent in 26.7% of all mutations. The response rate to chemotherapy was 40.0% in EGFR mutation-positive subgroup compared to 46.4% in EGFR mutation-negative subgroup (p=.57). The median time-to-progression (TTP) and overall survival (OS) for the patients with EGFR mutations were 4.9 months (95% CI, 3.0-7.2 months), and 19.0 months (95% CI, 14.7-26.1 months), respectively, compared to the median TTP and OS of patients with wild-type (6.9 months, 95% CI, 6.2-8.2 months in TTP; and 22.6 months, 95% CI, 18.9-24.6 months in OS), there were no statistically significant differences in TTP and OS. Therefore, clinical responsiveness to chemotherapy was not associated with EGFR mutations in advanced NSCLC patients.
In comparison with other related researches, our results were consistent with recent report published by Lee et al, but different from the results of researches (Bell and Eberhard et al) in INTACT and TRIBUTE studies. Bell et al showed that EGFR mutated patients treated with chemotherapy alone had a better overall survival compared with mutation negative patients (median OS, 19.4 months vs 9.2 months), but there were only 6.9% of East Asian patients in INTACT study. In our study, both mutated and wild-type advanced NSCLC patients had long survival (median OS, 19.6 and 22.6 months, respectively). Therefore, it was possible that EGFR mutational status was not a good predictive factor in East Asian patients with advanced NSCLC. | en |
dc.relation.reference | 1. 行政院衛生署: 衛生統計資料網 - 民國93年全民健康保險醫療統計年報. 2006/06/28
2. 行政院衛生署: 衛生統計資料網 - 民國94年臺灣地區主要癌症死亡原因. 2006/06/28
3. Schrump DS, Altorki NK, Henschke CL, et al. Non-Small Cell Lung Cancer. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Cancer. 7th ed.:753, 2005
4. Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncolgy Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003. J Clin Oncol 22:330-353, 2004
5. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
6. Fukouka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 21:2237-2246, 2003
7. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA:2149-2158, 2003
8. Fossella FV, DeV6re R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patinets with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362, 2000
9. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based therapy. J Clin Oncol 18:2095-2103, 2000
10. Miller V, Fossella F, DeVore R, et al: Docetaxel (D) benefits lung cancer symptoms and quality of life (QoL) in a randomized phase III study of non-small cell lung cancer (NSCLC) patients previously treated with platinum-based therapy. Proc Am Soc Clin Oncol 18:491 (abstract 1895), 1999
11. Harris RC, Chung E, Coffey RJ: EGF receptor ligands. Exp Cell Res 284:2-13, 2003
12. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787, 2003
13. Mukohara T, Kudoh S, Matsuura K, et al: Activated Akt expression has significant correlation with EGFR and TGF-alpha expressions in stage I NSCLC. Anticancer Res 24:11-17, 2004
14. Scagliotti GV, Selvaggi G, Novello S, et al: The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 10:4227s-4232s, 2004
15. Meert AP, Martin B, Delmotte P, et al: The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 20:975-81, 2002
16. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798-807, 2003
17. Selvaggi G, Novello S, Torri V, et al: Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 15:28-32, 2004
18. Nakamura H, Kawasaki N, Taguchi M, et al: Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 61:140-5, 2006
19. Hilsenbeck SG, Raub WA Jr, Sridhar KS: Prognostic factors in lung cancer based on multivariate analysis. Am J Clin Oncol 16:301-309, 1993
20. Ries LA: Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data. Semin Surg Oncol 10:21-30, 1994
21. Sugio K, Uramoto H, Ono K, et al: Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 94:896-903, 2006
22. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-46, 2005
23. Kosaka T, Yatabe Y, Endoh H, et al: Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer: Biological and Clinical Implications. Cancer Res 64:8919-8923, 2004
24. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-39, 2004
25. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-500, 2004
26. Sasaki A, Shimizu S, Endo K, et al: EGFR and ErB2 mutation status in Japanese lung cancer patients. Int J Cancer 118:180-184, 2006
27. Shih JY, Gow CH, Yu CJ, et al: Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 118:963-9, 2006
28. Tokumo M, Toyooka S, Kiura K, et al: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11:1167-73, 2005
29. Huang SF, Liu HP, Li LH, et al: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10:8195-203, 2004
30. Marchetti A, Martella C, Felicioni L, et al: EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857-65, 2005
31. Jännea PA, Gurubhagavatulab S, Yeapd BY et al: Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study. Lung Cancer 44:221-230, 2004
32. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) (abstract 7011). . Proc Am Soc Clin Oncol 23:617, 2004
33. Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353:133-44, 2005
34. Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-9, 2005
35. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-55, 2005
36. Han SW, Kim TY, Hwang PG, et al: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493-501, 2005
37. Inoue A, Suzuki T, Fukuhara T, et al: Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24:1-6, 2006
38. Bailey R, Kris M, Wolf M, et al: Gefitinib ('lressa', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone. Lung Cancer 41 71, 2003
39. Bell DW, Lynch TJ, Haserlat SM, et al: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23:8081-92, 2005
40. Lee KH, Han WS, Hwang PG, et al.: Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer. Jpn J Clin Oncol 36:344-350, 2006
41. Davis L, Lindley C: Neoplastic disorders and their treatment: General principles. In: Koda-Kimble MA, Young LY, Kradian WA, editors. Applied Therapeutics: The clinical use of drugs. 8th edition. Lippincott Williams & Wilkins:88-3, 2005
42. Yang SH, Mechanic LE, Yang P, et al: Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 11:2106-10, 2005
43. Taron M, Ichinose Y, Rosell R, et al: Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11:5878-85, 2005 | zh_TW |